In a report released yesterday, Matthew Mishan from KeyBanc reiterated a Buy rating on Steris Corp (STE), with a price target of $132. The company’s shares closed yesterday at $119.94, close to its 52-week high of $121.67.
According to TipRanks.com, Mishan is a 5-star analyst with an average return of 19.2% and a 78.0% success rate. Mishan covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Invacare Corp, and Cooper Co.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Steris Corp with a $135 average price target, implying a 12.6% upside from current levels. In a report issued on November 8, JMP Securities also maintained a Buy rating on the stock with a $135 price target.
Steris Corp’s market cap is currently $10.13B and has a P/E ratio of 32.45. The company has a Price to Book ratio of 3.25.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STERIS Plc engages in the provision of infection prevention and other procedural products and services. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies.